drugset / Trial / NCT05558124
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Phase 1
Recruiting
18 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Timeline
- Start
- 2023-02-16
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | 44 mg/m2 | — |
| Subject | CPX-351 | Other / unclassified | 100 mg/m2 | — |
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 3 mg/m2 | — |